SIMULTANEOUS ANALYTICAL METHOD DEVELOPMENT OF 6-MERCAPTOPURINE AND 6-METHYLMERCAPTOPURINE IN DRIED BLOOD SPOT USING ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY

Authors

  • Marlina Ika Department of Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
  • Rizka Andalusia Department of Research and Development, Dharmais Cancer Hospital, Jakarta, Indonesia.
  • Supandi Supandi Department of Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
  • Yahdiana Harahap Department of Pharmacy, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.

DOI:

https://doi.org/10.22159/ijap.2017.v9s1.80_87

Keywords:

6-Mercaptopurine, 6-Methylmercaptopurine, Dried blood spot, Ultra performance liquid chromatography tandem mass spectrometry, Validation

Abstract

Objective: 6-mercaptopurine (6-MP) is a chemotherapeutic agent in the antimetabolite class. It has to go through the metabolic pathway to form
6-methyl MP (6-MMP). This study aimed to obtain an optimum and validated method for the analysis of 6-MP and 6-MMP in dried blood spot (DBS)
samples simultaneously and to evaluate the potential for future drug concentration monitoring in DBS samples.
Methods: The quality control and calibration curves were made by spotting 40 μL blood on DBS paper and dried for 3 hrs. DBS papers were cut with a
diameter of 8 mm and extracted with acetonitrile-methanol (1:3) containing internal standard 5-fluorouracil (5-FU). Separation was performed with
waters acquity ultra performance liquid chromatography BEH C18 column of 1.7 μm (2.1×100 mm) with a mobile phase consisting of 0.1% formic
acid in water 0.1% formic acid in acetonitrile with gradient elution and a flow rate of 0.2 mL/minute. Mass detection was performed using Waters
Xevo TQD with positive electrospray ionization (ESI) for 6-MP and 6-MMP and negative ESI for 5-FU in the multiple reaction monitoring mode.
Results: The detection rates of 6-MP, 6-MMP, and 5-FU were 153.09>119.09, 167.17>126.03, and 129.09>42.05, respectively. This method was linear
with the range at 26-1000 ng/mL for 6-MP and 13-500 ng/mL for 6-MMP with consecutive r≥0.998 and ≥0.999, respectively. The % relative error
value and % relative standard deviation for accuracy and precision of intraday and interday were not more than 15% and not more than 20% at the
lower limit of quantification concentration, respectively.
Conclusions: This method fulfilled the requirements of selectivity, linearity, carry over, and matrix effects referring to the European Medicines Agency
guidelines.

Downloads

Download data is not yet available.

References

Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin

Pharmacol 1992;43(4):329-9.

Beaumais TA, Fakhoury M, Medard Y, Azougagh S, Zhang D,

Yakouben K, et al. Determinants of mercaptopurine toxicity in

paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin

Pharmacol 2010;71(4):575-84.

Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine/

Methotrexate maintenance therapy of childhood acute lymphoblastic

leukemia: Clinical facts and fiction. J Pediatr Hematol Oncol

;36(7):503-17.

Schmiegelow K, Bretton-Meyer U 6-mercaptopurine dosage and

pharmacokinetics influence the degree of bone marrow toxicity

following high-dose methotrexate in children with acute lymphoblastic

leukemia. Leukemia 2001;15(1):74-9.

Kirchherr H, Shipkova M, von Ahsen N. Improved method for

therapeutic drug monitoring of 6-thioguanine nucleotides and

-methylmercaptopurine in whole-blood by LC/MSMS using isotopelabeled

internal standards. Ther Drug Monit 2013;35(3):313-21.

Déglon J, Thomas A, Mangin P, Staub C. Direct analysis of dried

blood spots coupled with mass spectrometry: Concepts and biomedical

applications. Anal Bioanal Chem 2012;402(8):2485-98.

Wilhelm AJ, den Burger JC, Swart EL. Therapeutic drug monitoring

by dried blood spot: Progress to date and future directions. Clin

Pharmacokinet 2014;53(11):961-73.

Evans C, Arnold M, Bryan P, Duggan J, James CA, Li W, et al.

Implementing dried blood spot sampling for clinical pharmacokinetic

determinations: Considerations from the IQ consortium microsampling

working group. AAPS J 2015;17(2):292-300.

Hawwa AF, Al Bawab A, Rooney M, Wedderburn LR, Beresford MW,

McElnay JC. A novel dried blood spot-LCMS method for the

quantification of methotrexate polyglutamates as a potential marker for

methotrexate use in children. PLOS One 2014;9(2):e89908.

Published

30-10-2017

How to Cite

Ika, M., Andalusia, R., Supandi, S., & Harahap, Y. (2017). SIMULTANEOUS ANALYTICAL METHOD DEVELOPMENT OF 6-MERCAPTOPURINE AND 6-METHYLMERCAPTOPURINE IN DRIED BLOOD SPOT USING ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY. International Journal of Applied Pharmaceutics, 9, 168–171. https://doi.org/10.22159/ijap.2017.v9s1.80_87

Issue

Section

Original Article(s)

Most read articles by the same author(s)

<< < 1 2 3 > >>